Profile
Andrew Ernest Goodall served as a Non-Executive Director at Memphasys Ltd.
from 2012 to 2023.
He also held the same position at PrIME Biologics Pte Ltd.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
MEMPHASYS LTD
13.17% | 28/11/2023 | 180,149,529 ( 13.17% ) | 1 M $ | 29/04/2024 |
Former positions of Andrew Goodall
| Companies | Position | End |
|---|---|---|
| MEMPHASYS | Director/Board Member | 29/11/2023 |
PrIME Biologics Pte Ltd.
 PrIME Biologics Pte Ltd. BiotechnologyHealth Technology PrIME Biologics Pte Ltd. develops disposable therapeutic plasma manufacturing process. Its process doubles product yields while increasing product safety and removing viruses, bacteria, endotoxins, and prions. The firm’s process reduces the time it takes to produce multiple plasma products from days to hours. The company is headquartered in Singapore. | Director/Board Member | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| MEMPHASYS | Health Technology |
| Private companies | 1 |
|---|---|
PrIME Biologics Pte Ltd.
PrIME Biologics Pte Ltd. BiotechnologyHealth Technology PrIME Biologics Pte Ltd. develops disposable therapeutic plasma manufacturing process. Its process doubles product yields while increasing product safety and removing viruses, bacteria, endotoxins, and prions. The firm’s process reduces the time it takes to produce multiple plasma products from days to hours. The company is headquartered in Singapore. | Health Technology |
- Stock Market
- Insiders
- Andrew Goodall
